Cartesian Therapeutics Inc RNAC
About Quantitative Ratings
Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.
Is it the right time to buy, sell, or hold?
Start a free trial of Morningstar Investor to unlock exclusive ratings and continuous analyst coverage to help you decide if RNAC is a good fit for your portfolio.
News
-
Cartesian Therapeutics to Present at the ASGCT 27th Annual Meeting
-
Cartesian Therapeutics to Participate in the 23rd Annual Needham Virtual Healthcare Conference
-
Cartesian Therapeutics Announces New Employment Inducement Grants
-
Thinking about buying stock in WW International, Cartesian Therapeutics, Outfront Media, Genius Group, or PHX Minerals?
Trading Information
- Previous Close Price
- $21.94
- Day Range
- $21.47–22.49
- 52-Week Range
- $11.76–42.60
- Bid/Ask
- $21.93 / $22.37
- Market Cap
- $393.82 Mil
- Volume/Avg
- 35,506 / 57,325
Key Statistics
- Price/Earnings (Normalized)
- —
- Price/Sales
- 4.37
- Dividend Yield (Trailing)
- —
- Dividend Yield (Forward)
- —
- Total Yield
- 1.58%
Company Profile
Cartesian Therapeutics Inc is a clinical-stage biopharmaceutical company. The company uses its ImmTOR immune tolerance platform, which is designed to give rise to antigen-specific immunity, mitigating unwanted immune responses. It leverages its proprietary technology and manufacturing platform to introduce one or more mRNA molecules into cells to enhance their function. Unlike DNA, mRNA degrades naturally over time without integrating into the cell’s genetic material.
- Sector
- Healthcare
- Industry
- Biotechnology
- Stock Style Box
- Small Value
- Total Number of Employees
- 38
Comparables
Valuation
|
Metric
|
RNAC
|
EQRX
|
ACLX
|
|---|---|---|---|
Price/Earnings (Normalized) | — | — | — |
Price/Book Value | — | 0.97 | 5.51 |
Price/Sales | 4.37 | — | 22.27 |
Price/Cash Flow | — | — | — |
Price/Earnings
RNAC
EQRX
ACLX
Financial Strength
|
Metric
|
RNAC
|
EQRX
|
ACLX
|
|---|---|---|---|
Quick Ratio | 1.26 | 18.43 | 5.94 |
Current Ratio | 1.33 | 18.78 | 6.06 |
Interest Coverage | −83.26 | — | −23.39 |
Quick Ratio
RNAC
EQRX
ACLX
Profitability
|
Metric
|
RNAC
|
EQRX
|
ACLX
|
|---|---|---|---|
Return on Assets (Normalized) | −31.23% | −15.72% | −6.26% |
Return on Equity (Normalized) | — | −16.71% | −12.08% |
Return on Invested Capital (Normalized) | — | −21.31% | −13.11% |
Return on Assets
RNAC
EQRX
ACLX
Biotechnology Industry Comparables
|
Ticker
|
Name
|
Morningstar Rating for Stocks
|
Capital Allocation
|
Economic Moat
|
Market Cap
|
|---|---|---|---|---|---|
NVO
| Novo Nordisk A/S ADR | Vwkrczcvw | Cng | $566.6 Bil | |
VRTX
| Vertex Pharmaceuticals Inc | Msdcxzb | Xjhlh | $102.4 Bil | |
REGN
| Regeneron Pharmaceuticals Inc | Bhfshkhmq | Pdvkf | $98.3 Bil | |
MRNA
| Moderna Inc | Rwtqyxjl | Hdjrx | $42.7 Bil | |
ARGX
| argenx SE ADR | Ryckshzy | Rchs | $22.2 Bil | |
BNTX
| BioNTech SE ADR | Pgcqgvx | Hgkw | $21.2 Bil | |
ALNY
| Alnylam Pharmaceuticals Inc | Mfdwbjy | Jxwlp | $18.6 Bil | |
BMRN
| Biomarin Pharmaceutical Inc | Nkxpwmrw | Sxzhd | $15.6 Bil | |
RPRX
| Royalty Pharma PLC Class A | Qghwkxvkv | Brgyknt | $12.7 Bil | |
INCY
| Incyte Corp | Brqxvpc | Zqxkhn | $11.8 Bil |